Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Donaldson, F. Accurso, S. Rowe, J. Clancy, M. Boyle, J. Dunitz, P. Durie, S. Sagel, D. Hornick, M. Konstan, R. Moss, J. Pilewski, R. Rubenstein, A. Uluer, M. Aitken, S. Freedman, L. Rose, N. Mayer-Hamblett, Q. Dong, J. Zha, A. Stone, E. Olson, C. Ordonez, P. Campbell, M. Ashlock, B. Ramsey (Chapel Hill, Aurora, Birmingham, Baltimore, Minneapolis, Iowa City, Cleveland, Palo Alto, Pittsburgh, Philadelphia, Boston, Seattle, Cambridge, Bethesda, United States Of America; , Canada). Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation. Eur Respir J 2010; 36: Suppl. 54, 359

Member's Comments

No comment yet.

Related content which might interest you: Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation Source: Annual Congress 2011 - Cystic fibrosis: detection and monitoring of early lung disease Year: 2011 Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Source: Eur Respir Rev 2013; 22: 66-71 Year: 2013 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012 Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011 Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a Source: Eur Respir J 2010; 36: 311 Year: 2010 How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016 CFTR correctors and potentiators: pre-clinical studies in mouse models for CF Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 CFTR dysfunction and its relationship to phenotype and development of new treatments restoring CFTR function Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults Year: 2013 A three miRNA signature regulates the CF transmembrane conductance regulator (CFTR) in cystic fibrosis airway epithelium Source: Annual Congress 2011 - Epithelial cells: role in health and disease Year: 2011 Potentiating and correcting mutant CFTR in patients with cystic fibrosis Source: Eur Respir Monogr 2014; 64: 129-149 Year: 2014 Rescue of CFTR function impaired by mutations in exon 15 Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Allosteric inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) slows airway mucus transport in normal sheep Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 A novel CFTR mutation found in a Chinese cystic fibrosis patient Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005 Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease Source: Eur Respir J 2009; 34: 772 Year: 2009